N/A
Completed N=41
Electroconvulsive Therapy Amplitude Titration
Source: ClinicalTrials.gov NCT04621786 ↗Enrolled (actual)
41
Serious AEs
3.5%
Results posted
Jun 2023
Primary outcomePrimary: Beta Coefficient From Linear Regression of Amplitude-determined Seizure (Independent Variable) and Ebrain (Dependent Variable) — -.0001054 beta coefficient from linear regression
Summary
This study is focused on advancing ECT treatment for older adults with depressive disorders by refining neuromodulation stimulus parameters to improve efficacy and cognitive safety.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Beta Coefficient From Linear Regression of Amplitude-determined Seizure (Independent Variable) and Ebrain (Dependent Variable) |
-.0001054 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of major depressive disorder
- Clinical indications for ECT with right unilateral electrode placement
- Right-handed
- Age range between 50 and 80 years
Exclusion Criteria
- Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury, epilepsy, Alzheimer's disease)
- Other psychiatric conditions (e.g., schizophrenia, bipolar disorder)
- Current drug or alcohol use disorder (except for nicotine); and 4) contraindications to MRI.
Data sourced from ClinicalTrials.gov (NCT04621786). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.